Development of therapeutic-grade small interfering RNAs by chemical engineering

Jesper B. Bramsen* and Jørgen Kjems

Interdisciplinary Nanoscience Center, Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark

Keywords: RNAi, siRNA, chemical modification, immunogenicity, off-target effect, LNA, OMe, siRNA therapeutic

Recent successes in clinical trials have provided important proof of concept that small interfering RNAs (siRNAs) indeed constitute a new promising class of therapeutics. Although great efforts are still needed to ensure efficient means of delivery in vivo, the siRNA molecule itself has been successfully engineered by chemical modification to meet initial challenges regarding specificity, stability, and immunogenicity. To date, a great wealth of siRNA architectures and types of chemical modification are available for promoting safe siRNA-mediated gene silencing in vivo and, consequently, the choice of design and modification types can be challenging to individual experimenters. Here we review the literature and devise how to improve siRNA performance by structural design and specific chemical modification to ensure potent and specific gene silencing without unwarranted side-effects and hereby complement the ongoing efforts to improve cell targeting and delivery by other carrier molecules.

Edited by:
Kumiko Ui-Tei, University of Tokyo, Japan

Reviewed by:
Terrence Chi-Kong Lau, City University of Hong Kong, Hong Kong
Heh-In Im, Korea Institute of Science and Technology, South Korea

*Correspondence:
Jesper B. Bramsen, Interdisciplinary Nanoscience Center, Department of Molecular Biology and Genetics, Aarhus University, C.F. Mollersalle Building 1130, 8000 Aarhus C, Denmark.
e-mail: jebb@mb.au.dk

SILENCING GENES USING NUCLEIC ACID
NUCLEIC ACID-BASED THERAPEUTICS

Nucleic acid-based therapeutics promise to overcome the major limitation of existing medicine, which can currently only target a limited number of proteins involved in disease pathways (Melnikova, 2007). Such promise rely on the high predictability of nucleic acid base-pairing which provides an ideal framework for gene silencing technologies (GSTs) by offering unparalleled specificity, rapidity of development and renders, at least in principle, all human genes “druggable” (Krieg, 2011). Pioneering work in the 1970–1980s established the nucleic acid antisense technology as an universal GST by developing synthetic antisense oligonucleotides (ASOs) and ribozymes, which base pair to and inhibit the function of any desired messenger RNA (mRNA; Zamecnik and Stephenson, 1978; Potera, 2007). Today, two ASO-based drugs have been commercialized and several modern antisense design variants (Monia et al., 1993; Highleyman, 1998; Elbashir et al., 2001a) provided researchers with an unprecedentedly powerful gene silencing tool. The obvious therapeutic potential of siRNAs immediately renewed the scientific and commercial interest in developing nucleic acid drugs capable of low-dose, non-toxic targeting of mRNAs to treat human diseases. As compared to other nucleic acid-based technologies, siRNA benefits from harnessing endogenous RNAi pathways to effectuate gene silencing (Figure 1); upon introduction of synthetic siRNAs into the cell cytoplasm they are incorporated into an RNA-induced silencing complex (RISC; Hammond et al., 2001) by a RISC loading complex (RLC; Maniataki and Mourelatos, 2005) containing the RNase III enzyme Dicer (Bernstein et al., 2001). By sensing the thermodynamic asymmetry of siRNA duplex ends (Khvorova et al., 2003; Schwarz et al., 2003), RLC loads the siRNA guiding antisense strand into a cleavage-competent RISC containing Argonaute 2 (Ago2; Martinez and Tuschl, 2004), whereas the passenger sense strand (SS) is cleaved and released (Matranga et al., 2005; Negrello et al., 2006). Consequently, Ago2-RISC will efficiently guide and effectuate multiple rounds of target RNA cleavage resulting in gene “knockdown” (KD; Hutvagner and Zamore, 2002). Furthermore, the structural similarity of endogenous microRNAs (miRNAs) and artificial siRNA triggers may be expected to render these undetectable to cellular sensors of (foreign) dsRNA thereby preventing induction of innate immune-responses. In effect, harnessing siRNA to effectively enter the endogenous RNAi pathway translates into high silencing efficiencies, predictability, and reliability (Bertrand et al., 2002) but concurrently hold the potential to disturb endogenous gene regulation by the native inhabitants of the RNAi pathway, the miRNAs.

EXPLOITING RNAi PATHWAYS FOR THERAPEUTICS

The discovery of RNA interference (RNAi), gene silencing by double-stranded RNA (dsRNA), in the nematode worm C. elegans in 1998 (Fire et al., 1998) and the observation in 2001 that synthetic 21-mer dsRNA, named small interfering RNA (siRNA), triggered potent and specific gene silencing in mammalian cells (Elbashir et al., 2001a) provided researchers with an unprecedentedly powerful gene silencing tool. The obvious therapeutic potential of siRNAs immediately renewed the scientific and commercial interest in developing nucleic acid drugs capable of low-dose, non-toxic targeting of mRNAs to treat human diseases. As compared to other nucleic acid-based technologies, siRNA benefits from harnessing endogenous RNAi pathways to effectuate gene silencing (Figure 1); upon introduction of synthetic siRNAs into the cell cytoplasm they are incorporated into an RNA-induced silencing complex (RISC; Hammond et al., 2001) by a RISC loading complex (RLC; Maniataki and Mourelatos, 2005) containing the RNase III enzyme Dicer (Bernstein et al., 2001). By sensing the thermodynamic asymmetry of siRNA duplex ends (Khvorova et al., 2003; Schwarz et al., 2003), RLC loads the siRNA guiding antisense strand into a cleavage-competent RISC containing Argonaute 2 (Ago2; Martinez and Tuschl, 2004), whereas the passenger sense strand (SS) is cleaved and released (Matranga et al., 2005; Negrello et al., 2006). Consequently, Ago2-RISC will efficiently guide and effectuate multiple rounds of target RNA cleavage resulting in gene “knockdown” (KD; Hutvagner and Zamore, 2002). Furthermore, the structural similarity of endogenous microRNAs (miRNAs) and artificial siRNA triggers may be expected to render these undetectable to cellular sensors of (foreign) dsRNA thereby preventing induction of innate immune-responses. In effect, harnessing siRNA to effectively enter the endogenous RNAi pathway translates into high silencing efficiencies, predictability, and reliability (Bertrand et al., 2002) but concurrently hold the potential to disturb endogenous gene regulation by the native inhabitants of the RNAi pathway, the miRNAs.

siRNA AS A THERAPEUTIC PLATFORM

Small interfering RNAs have gained increasing popularity in vivo (Behlke, 2006, 2008; Higuchi et al., 2010; Lares et al., 2010)
The most widely used siRNA type is the “canonical” synthetic 21-mer siRNA composed of two 21 nt RNA strands annealed to form a 19-bp dsRNA duplex stem and 2 nt 3'-overhangs at both ends (the passenger strand is shown in black and the guide strand is shown in red). Also synthetic, dicer-substrate 27-mer siRNAs (DsiRNA) has provided a popular alternative. Both design types can be delivered in vivo either unformulated or upon formulation of various types of delivery agents into the cell cytoplasm (light gray circle) where siRNAs are taken up by a RISC loading complex (RLC), which upon a dicer cleavage event (27-mer designs only, 21-mer siRNAs are dicer-independent) is structurally rearranged into a pre-RISC. Here the siRNA passenger strand is cleaved leading to the establishment of an active RISC that assists and ensures efficient degradation of RNA target sharing perfect (Continued)
and the number of RNAi-based preclinical and clinical trials have increased rapidly over recent years with ~22 different siRNA or short hairpin RNA (shRNA) therapies reaching clinical testing for the treatment of at least 16 diseases (http://maps.google.com/maps/ms?ie=UTF8&msa=0&msid=1176964860214375789.000476c449bf397d6d0&DeVincentzeno et al., 2008; Davis et al., 2010; Leachman et al., 2010; Burnett et al., 2011; Davidson and McCray, 2011; Burnett and Rossi, 2012). This is truly an amazing achievement for a such a fledgling technology considering that conventional development of small-molecule drugs takes at least 5–7 years for preparing a single drug candidate for human clinical trials (Krieg, 2011). For comparison, the first clinical trial of a siRNA-based drug was initiated in 2004 only 3 years after the initial application of siRNA in mammalian cell cultures (Shukla et al., 2010) and successful siRNA designs may easily be adaptable to other target.

**siRNA NEED CHEMICAL ENGINEERING TO SUCCEED AS THERAPEUTIC PLATFORM**

Building superior siRNAs is a combination of choosing an optimal siRNA-target sequence, optimal type of siRNA design, and, importantly, to introduce the proper combination of chemical modifications to suit the particular application. As a scientific tool in mammalian cell cultures, the potency and specificity of unmodified synthetic siRNA may be considered sufficient, yet chemical engineering of siRNAs is a prerequisite to transform them into a novel class of safe therapeutics, a natural progression similar to the development of second generation ASO (Potera, 2007). Recent concerns regarding siRNA delivery and safety have dampened initial excitement and Big Pharma have recently down sized their investments in RNAi R&D (Ledford, 2010; Krieg, 2011; Schmidt, 2011). In particular, the size, lability, and negative charge of siRNAs severely complicate efficient intracellular delivery *in vivo* (Meade and Dowdy, 2009) and siRNA may trigger innate immune-response and lead to unintended deregulation of endogenous gene expression in several ways, as described in the following sections. Encouragingly, these concerns may be fully addressable by careful chemical modification of the synthetic siRNA molecule, an ongoing task that have already gone a long way; the first KD of an endogenous gene, apolipoprotein B (ApoB), was observed in mouse livers after low-pressure intravenous injections of a chemically modified, but naked (non-formulated) siRNA already in 2004 (Soutschek et al., 2004). Also, the first successful KD via RNAi of a cancer target gene in a human, the M2 subunit of ribonucleotide reductase (RRM2), was achieved in 2010 upon systemic siRNA delivery, a holy grail in siRNA therapeutics, using siRNA nanoparticles in a clinical phase-I trial in tumors from melanoma patients (Davis et al., 2010).

**STRUCTURAL siRNA DESIGNS**

Today, a variety of siRNA design types are available for gene silencing each offering benefits and disadvantages (*Figure 2*): The by far most popular siRNA design mimics natural Dicer cleavage products and comprises a 21 nucleotide (nt) guiding strand antisense to a given RNA target and a complementary passenger strand annealed to form a siRNA duplex with a 19-bp dsRNA stem and 2 nt 3’ overhangs at both ends (here referred to as canonical 21-mer siRNAs; Elbashir et al., 2001a,b). Longer design types, collectively referred to as Dicer-substrate siRNAs (DsirRNAs) structurally mimic various Dicer substrates to enhance incorporation into RNAi pathways and potentially siRNA potency (Kim et al., 2005; Rose et al., 2005; Siolas et al., 2005; Amazguiouei et al., 2006; Collingwood et al., 2008; Hefner et al., 2008; Tanudji et al., 2009). Also shorter or truncated siRNA designs are gaining popularity such as 16-mer siRNA (Chu and Rana, 2008), shRNAs with RNA stems ≤19 bp (Ge et al., 2009a,b), blunt 19-bp siRNAs (Czauderna et al., 2003; Prakash et al., 2005; Hogrefe et al., 2006; Ghosh et al., 2009), asymmetrical siRNAs (aiRNA; Sun et al., 2008), and asymmetric shorter-duplex siRNA (as-siRNA; Chang et al., 2009). Finally, fork siRNAs (Hohjoh, 2004; Petrova Kruglova et al., 2010), single-stranded siRNAs (ss-siRNAs; Martinez et al., 2002; Holen et al., 2003; Hall et al., 2006), Dumbbell-shaped circular siRNAs (Abe et al., 2011), bulge-siRNA (Dua et al., 2011), and sisiRNAs (Bramsen et al., 2007) have been successfully utilized, but may require more testing to qualify as a therapeutic siRNA platform. Recently, siRNAs have also been incorporated in larger nucleic acid structures (Afonin et al., 2011; Grabow et al., 2011) with the prospect of enhancing delivery and bio-availability in vivo.

**TOLERANCES FOR CHEMICAL MODIFICATION OF siRNAs**

The chemical synthesis of siRNAs allows the position-specific incorporation of chemically modified nucleotides in the siRNA to modulate, e.g., thermostability, nuclease resistance, duplex structure, and base-pairing properties. For a decade, the compatibility of a diversity of chemical modifications with siRNA function has been mapped by empirical testing. Early siRNA chemical modification schemes quite naturally focused on modification types previously used to potentiate and stabilize ASOs (reviewed in Kurreck,
and target RNA is mediated only by the 5′ proximal siRNA seed region (positions 2–8 of the RISC-associated strand) selectively exposed to the solvent (Wang et al., 2008) and subsequent Ago2-mediated cleavage of target RNA requires forming of an RNA-like A-type helix structure between the guide strand and the target spanning both the seed region and around the cleavage site (opposite of guide strand position 10/11; Meister et al., 2004) hereby explaining the sensitivity of these AS positions to modification.

TOOLS FOR CHEMICAL MODIFICATION OF siRNAs

Mainly four classes of chemical modifications is utilized to modify ASOs and now siRNAs: (i) modification of the negatively charged phosphodiester backbone is primarily utilized to enhance siRNA nuclease resistance or affect RNA biodistribution and cellular uptake; (ii) modifications at the ribose 2′-OH group is widely used to modulate most aspects of siRNA behavior including modulating siRNA nuclease resistance, potency, specificity of silencing and to reduce siRNA immunogenicity; (iii) modifications of the ribose ring and nucleoside base is utilized to modulate siRNA stability and base-pairing properties; (iv) dual modifications harbor two modified functionalities in a single nucleotide and especially the combination of backbone and ribose modifications with 2′ OH substitutions are currently gaining momentum (for a non-exhaustive selection of popular chemical modification types in siRNA design see Figure 3).

siRNA BACKBONE MODIFICATION

A classic and popular phosphate backbone alteration is the phosphorothioate (PS) modification where one of the non-bridging phosphate oxygens is replaced with sulfur (Braasch et al., 2004). Also phosphorodithioate (PS2) substitutions, where both non-bridging oxygen atoms are replaced, were recently tested in siRNA designs and slightly increased siRNA potencies and nuclease resistance as compared to PS and unmodified siRNA (Yang et al., 2012). Moderately PS-modified siRNAs support efficient RNAi, yet effects are very position-dependent (Amazguioui et al., 2003; Braasch et al., 2003; Chiu and Rana, 2003; Grunweller et al., 2003; Harborth et al., 2003; Meister et al., 2004) hereby explaining the sensitivity of these AS positions to modification.
Bramsen and Kjems

FIGURE 3 | Popular chemical modification types in siRNA design. RNA, ribonucleic acid; PS, phosphothioate; PS2, phosphodiithoate; EA, 2′-aminoethyl; DNA, deoxyribonucleic acid; 2′-F, 2′-fluoro; 2′-OMe, 2′-O-methyl; 2′-MOE, 2′-O-methoxyethyl; F-ANA, 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid; HM, 4′-C-hydroxymethyl-DNA; LNA, locked nucleic acid; carboxylic LNA, 2′,4-carboxylic-LNA-locked nucleic acid; OXE, oxetane-LNA; UNA, unlocked nucleic acid; 4′-S, 4′-thioribonucleic acid; ME-SRNA, 2′-O-Me-4′-thioribonucleic acid; ANA, altitol nucleic acid; HNA, hexitol nucleic acid; B, base.

2003; Harborth et al., 2003; Choung et al., 2006) but extensive PS modification reduces silencing (Chiu and Rana, 2003; Hall et al., 2004) and has toxic side-effects (likely due to a tendency to bind non-specifically to cellular membrane proteins; Amarzguioui et al., 2003; Harborth et al., 2003). Still, moderate PS modification levels have been widely and successfully combined with ribose 2′-OH modifications in both ASO and siRNA designs to stabilize naked RNA for systemic application in mice (Soutschek et al., 2004; Elmen et al., 2008). Both PS and PS2 will slightly thermo-destabilize siRNA duplexes (≈0.5°C per modification; Eckstein, 2002; Amarzguioui et al., 2003; Harborth et al., 2003; Yang et al., 2012). Substitution of the phosphodiester linkage with a boranophosphate linkage has been explored in gene silencing using a canonical siRNA (Hall et al., 2004) or single-stranded siRNAs (Hall et al., 2006). Similarly to PS and PS2, boranophosphate linkages decrease the $T_m$ of RNA duplexes by $≈0.5$–$0.8$°C per modification (Li et al., 2007) and enhances nuclease resistance as compared to unmodified siRNAs, yet is better-tolerated in siRNA
design than PS (Hall et al., 2004). Still this modification type has not been widely used.

A phosphonoacetaete (PACE) modification consists of an acetate group in place of a non-bridging oxygen in an internucleotide phosphate linkage whereas a thioPACE modification is an analogous substitution in a phosphorothioate linkage. Both modifications are completely resistant to degradation and PACE is electrochemically neutral if esterified with, e.g., methyl groups (Sheehan et al., 2003), which allows modified oligonucleotides to be taken up by cells in the absence of delivery reagents (Yamada et al., 2007). Also dual modification types combining 2′-OMe and PACT/ThioPACT have recently been tested in siRNA design (see below). Finally, amide linkages (Iwase et al., 2007) and 2′,5′-linkages (Prakash et al., 2006) have been found to enhance nuclease resistance of siRNAs, yet are little used so far.

**RIBOSE 2′-OH SUBSTITUTIONS**

Modifications of the ribose 2′-OH is the most popular approach in siRNA design in which the 2′-OH is either substituted with other chemical groups or the 2′-oxygen is "locked" via intramolecular linkages as in bridged nucleic acids (BNAs). So far, the small electronegative 2′ substituents such as 2′-fluoro (2′-F), DNA (2′-H), 2′-O-methyl (2′-OMe) are most widely used as they are well-tolerated, will generally enhance siRNA nuclease resistance and not dramatically affect siRNA thermostability, dsRNA duplex conformation nor siRNA activity.

Fluorine substitution (2′-F) slightly stabilizes dsRNA duplexes (~1°C increase in $T_m$ per modification; Freier and Altman, 1997; Allerson et al., 2005), is among the best tolerated modification types and therefore allows the creation of highly modified, active siRNAs: both strands tolerate 2′-F modification at most positions (Braasch et al., 2003; Chiu and Rana, 2003; Harborth et al., 2003; Prakash et al., 2005; Choung et al., 2006; Manoharan et al., 2011) and substitution of all siRNA pyrimidines was reported to greatly enhance serum stability and to support effective silencing in vitro and in vivo (Capodici et al., 2002; Lazer et al., 2004; Morrissey et al., 2005a). Also, 2′-F has proven superior during an application in vivo using a mouse model for silencing of the factor VII gene as directly compared to other 2′-modifications described above. Still, bulky 2′-modifications such as 2′-O-MOE, 2′-O-allyl and others are only tolerated at certain positions within the siRNA duplex, likely owing to their distortion of RNA helix structure essential to Ago2 cleavage (Amarguizouoi et al., 2003; Prakash et al., 2005; Odadzic et al., 2008; Bramsen et al., 2009). This somewhat limits their use for general siRNA design as similar enhancements in, e.g., nuclease resistance may be obtained by the better-tolerated, smaller 2′-substitutions described above. Still, bulky 2′-modifications are best tolerated at the 3′-ends of siRNA strands (Odadzic et al., 2008), where they may be used to modulate thermodynamic stability and duplex asymmetry to enhance siRNA potency: e.g., an 2′-aminoethyl modification in the passenger strand 3′-end can enhance siRNA potency, likely by affecting strand selection during RISC loading (Bramsen et al., 2009). Still, bulky 2′-modifications are not widely used other than in siRNA overhangs to enhance nuclease resistance (Amarguizouoi et al., 2003; Prakash et al., 2005; Odadzic et al., 2008; Bramsen et al., 2009).

**BRIDGED NUCLEIC ACIDS**

Another class of 2′-modification is the BNA in which the ribose 2′-oxygen is linked to the 4′-carbon via a methylene bridge as in Locked Nucleic Acid (LNA; Wengel et al., 2001) and carboxycyclic-LNA (Srivastava et al., 2007; Bramsen et al., 2009), via an ethylene bridge as in ethylene-bridged nucleic acid (ENA; Hamada et al., 2002) and carboxycyclic-ENA (Srivastava et al., 2007; Bramsen et al., 2009), or to the 1′-carbon as in oxetane (OXE; Pradeepkumar et al., 2003; Bramsen et al., 2009). This radical modification type generates nucleotides with interesting properties to siRNA design;
The methylene bridge in the very popular LNA-modification locks the sugar moiety in the RNA-helical C3′-endo conformation, which additively increases RNA duplex thermostability by 2–10˚C per LNA (Petersen and Wengel, 2003). Although this dramatic thermo-stabilization limits siRNA modification levels by LNA (Braasch et al., 2003; Gruenweller et al., 2003; Elmén et al., 2005), it provides unique opportunities to modulate the local thermodynamic profile within the siRNA duplex to optimize strand selection and thereby enhance specificity (Elmén et al., 2005; Bramsen et al., 2007, 2009), to enhance nuclease resistance in vitro (Braasch et al., 2003; Bramsen et al., 2009) and in vivo (Mook et al., 2007; Glud et al., 2009) and reduce siRNA immunogenicity (Hornung et al., 2005) as described in the following sections. Also, the thermo-stabilizing LNA may be used to ensure the integrity of siRNA designs relying on only short regions of oligo base-pairing such as the three stranded siRNA design (Brams et al., 2007). As a note of caution, LNA-modified ASO can induce profound hepatotoxicity in mice (Swayze et al., 2007) albeit this is not observed in other studies, e.g., in primates (Elmen et al., 2008).

ALTERATION OF THE RIBOSE MOIETY

Modification types based on sugar moieties other than ribose have been successfully used in siRNA designs upon incorporation of, e.g., altritol nucleic acid (ANA), hexitol nucleic acid (HNA), 2′-deoxy-2′-fluoroarabinonucleic acids (2′-F-ANA), and cyclohexenyl nucleic acid (CeNA) nucleotides, which are based on altritol, hexitol, arabinose, and cyclohexenyl sugars, respectively (Dowler et al., 2006; Fisher et al., 2007, 2009; Nauwelaerts et al., 2007; Watts et al., 2007; Bramsen et al., 2009).

The 2′-F-ANA modification is structurally similar to DNA (C2′-endo conformation) and increases the \( T_m \) of the siRNA duplex by ~0.5–0.8˚C per modification and will, due its structural similarity to DNA, structurally distort siRNA duplexes making it little suited to modify the seed regions of the guide strand. Full modification of the SS can lead to significant enhancements in potency and nuclease resistance and 2′-F-ANA-modification may be particular useful in the guide strand to create high-affinity 3′ overhangs, similarly to DNA (Dowler et al., 2006; Watts et al., 2007). Moreover, heavily modified siRNAs that contain combinations of 2′-F-ANA and 2′-F or LNA show superior properties (Deleavy et al., 2010).

The ANA modification will slightly enhance siRNA thermostability, are stable against enzymatic degradation and can moderately enhance siRNA activity and silencing duration upon incorporation into both duplex 3′-ends (Fisher et al., 2007) whereas overhang modification slightly decrease RISC affinity (Maiti et al., 2011). Similarly, the incorporation of HNA at both strand 3′-ends enhanced silencing potency, serum stability, and silencing duration of a siRNA against B-Raf, even more so than observed for ANA-modifications upon direct comparison (Fisher et al., 2009). Finally, CeNA modification of passenger and guide strand 3′-ends can increase siRNA potency and nuclease resistance (Nauwelaerts et al., 2007).

A radical modification of the ribose is found in unlocked nucleic acid (UNA) which is an acyclic derivative of RNA lacking the C2′–C3′-bond of the ribose ring that still structurally mimic unmodified RNA upon incorporation into RNA duplexes. Rather uniquely, the incorporation of UNA residues strongly destabilizes the duplex by 5–8˚C per UNA monomer hereby allowing dramatic local destabilization of siRNA duplex and guide strand/target interactions (Langkjaer et al., 2009). As a consequence, extensive UNA modification will prevent annealing of siRNA strands and limits modification levels to 2–3 UNAs within the duplex region (Laursen et al., 2010). Still, even modest UNA modification has proven very successful in enhancing siRNA biostability and function in vivo (Laursen et al., 2010), in preserving the potency of extensively thermo-stabilized siRNA (such as in extensively LNA-modified siRNAs; Laursen et al., 2010) and in reducing siRNA off-targeting (Brams et al., 2010; Vaish et al., 2011) as described in Section “Reducing siRNA Off-Target Effects by Chemical Modification.”

Finally, 4′-thio-modified nucleotides (4′-S RNA) contain a sulfur atom instead of the 4′-carbon of the ribose ring and can enhance nuclease resistance, target affinity, and siRNA potency. Stretches of 4′-thio-RNA were well-tolerated in both siRNA strands albeit only at certain positions in the guide strand (Hoshika et al., 2005; Dande et al., 2006) and sequence-specific effects of 4′-thio modifications have been reported (Hoshika et al., 2007). Instead, 4′-thio-RNA can be utilized as a “dual modification” by combining it with 2′-OMe (Dande et al., 2006) or 2′-F (Takahashi et al., 2009), as described below.

BASE MODIFICATION

Chemical modification of the RNA nucleobases is still less commonly used in siRNA design (reviewed in Peacock et al., 2011). A number of modified nucleotide bases, such as 5-bromo-, 5-iodo-, 2-thio-, 4-thio-, dihydro-, and pseudo-uracil, have been tested with the prospect of to stabilize base-pairing and to enhance base pairing specificity; 5-bromo- and 5-iodo-uracil slightly reduced siRNA potency (Chiu and Rana, 2003), whereas 2-thio- and pseudo-uracil were reported to enhance siRNA potency (Sipa et al., 2007) and to reduce cellular immune responses (Hornung et al., 2006).

DUAL MODIFICATIONS

The combination of two modified functionalities on a single ribose in so-called “dual modification” types has recently been tested in siRNA design to address that 2′-modification or backbone modification alone typically confers insufficient nuclease resistance and pharmacokinetic properties for siRNA applications in vivo.

The 4′-Thio (4′-S) modification has been combined with a variety of 2′-substitutions such as 2′-OMe, 2′-O-MOE, 2′-F, or 2′-F-ANA (Dande et al., 2006; Watts et al., 2007; Takahashi et al., 2009); Most significantly, 2′-OMe/4′-S modification can significantly enhance serum stability as compared to 2′-OMe (or 2′-F) modification alone and does not affect duplex thermostability, whereas 2′-F-ANA/4′-S increase the \( T_m \) by ~1.0˚C per modification but does not improve serum stability beyond simple 2′-OMe modification (Takahashi et al., 2009). Recently, 2′-OMe/4′-S modification was shown to significantly enhance siRNA silencing longevity, an effect that was attributed to enhanced intracellular siRNA stability (Takahashi et al., 2012). The 2′-F-ANA/4′-S modification, which decreases the \( T_m \sim 1.0–1.4˚C \) per modification, is only tolerated at low modification levels and does not immediately offer unique advantages in siRNA potencies (Watts et al., 2007).
Combining 2′-OMe and PS modification to create 2′-OMePS has generated fully modified passenger strands with dramatically enhanced nuclease resistance whereas similar modification rendered guide strands inactive (Kraynack and Baker, 2006). This remarkable nuclease resistance seems well suited for ASO design: in a phase-I clinical trial, the 2′-OMePS-modified ASO, PRO051, could successfully restore specific exon skipping during mRNA splicing leading to restoration of dystrophin expression in patients with Duchenne’s muscular dystrophy (van Deutekom et al., 2007).

Combination of 2′-OMe and PACT or thioPACT linkages decrease the $T_m$ of RNA duplexes $~0.75–1^\circ C$ per modification as compared to 2′-OMe-modified duplexes alone (which are stabilized compared to unmodified dsRNA; see above; Threlfall et al., 2012). PACT and ThioPACT enhance siRNA stability, and will reduce siRNA potency, even if only placed in the passenger strand, and (double-stranded) siRNA are not efficiently taken up by cells in the absence of transfection reagents, in contrast to modified single-stranded oligonucleotides (Threlfall et al., 2012). Finally, 4′-aminomethyl-2′-OMe dual modification of siRNAs will slightly lower the $T_m$ ($~1^\circ C$/modification) compared to the unmodified duplex, can increase siRNA serum stability and modifications are well-tolerated at various positions in the passenger strand, but not in the seed region of the guide strand (Gore et al., 2012).

DESIGNING POTENT siRNAs BY CHEMICAL ENGINEERING

A natural priority in siRNA design is to ensure maximal gene silencing at low concentrations, i.e., to obtain IC50 values in the nano or pico-molar range suitable for silencing in vivo, where siRNA delivery is often difficult. Important knowledge of the most influential factors for siRNA potency has been obtained by empirical testing of large libraries of unmodified siRNAs in cell culture and subsequent bio-informatical data mining (Reynolds et al., 2004; Huesken et al., 2005; Vert et al., 2006; Ladunga, 2007; Klingelhofer et al., 2009; Wang et al., 2009a). Several studies propose nucleotide base preferences at selected positions relative to the target sequence such as G/C at position 1, A/U at positions 10 and 19, more than three A/Us between positions 13 and 19 (Amarzguioui and Pryde, 2004; Reynolds et al., 2004; Ui-Tei et al., 2004; Jagla et al., 2005), and position-independent overrepresentation of certain di- and tri-nucleotide motifs (Ebalunode et al., 2011), and relatively U-rich antisense strands (Ladunga, 2007; Wang et al., 2010), especially in the 5′-end (Ui-Tei et al., 2004). An obvious question is whether chemical modification can enhance the potencies of already well-designed unmodified siRNAs. Indeed, numerous studies report the improvement of siRNA potency by chemical modification; typically improvements in potency are moderate, less than twofold, and only in few cases has chemical modification led to dramatic enhancements of siRNA potency (Allerson et al., 2005), effects, which may be too sequence-specific for general siRNA design (Koller et al., 2006). Hereby chemical modification strategies may not necessarily create “super-potent” siRNAs (as compared to well-designed unmodified siRNAs), but can be efficiently used to counteract reductions in potency encountered while addressing other siRNA shortcoming in siRNA stability, off-targeting, immunogenicity, or to tweak siRNA thermodynamics when targeting a defined target with a non-optimal sequence composition.

MODULATING siRNA THERMOSTABILITY AND -ASYMMETRY TO ENHANCE siRNA POTENCY

Of interest to siRNA chemical modification strategies it is notable that most of the siRNA sequence preferences described above may reflect an optimal siRNA thermodynamic profile that ensures efficient handling by RNAi proteins. Most prominently, siRNA strand selection during RISC activation is determined by the thermodynamic asymmetry between siRNA duplex ends: the siRNA strand having its 5′-end embedded at the thermodynamically least stable end is preferentially employed as guide stand within RISC (Khvorova et al., 2003; Schwarz et al., 2003). Consequently, siRNAs should be designed to be thermodynamically asymmetric either by simply choosing AU base pairs at the 5′ terminal positions of the guide stand and/or GC base pairs in its 3′-end or, more advanced, by engineering proposed optimal difference in Gibbs free energy between duplex ends (Khvorova et al., 2003; Shabalina et al., 2006), either by sequence choice or by introducing mismatches or chemical modifications. In this regard, many chemical modification types are ideal tools to position-specifically modulate siRNA thermostability; modifications such as LNA, 2′-F, 2′-OMe are stabilizing, whereas other such as UNA, OXE, and PS are destabilizing. Chemical screens have identified that modifications ensuring preferential loading of the intended guide strand into RISC will often enhance potency; destabilizing modification in the passenger duplex 3′-end such as OXE, ethylamino, UNA, dihydrouracil, or PS (Elmén et al., 2005; Li et al., 2005; Bramsen et al., 2009; Yang et al., 2012) and stabilizing modification in the passenger strand 5′-end such as LNA (Elmén et al., 2005) and/or stabilizing modification in the guide strand duplex 3′-end improve siRNA potency (Bramsen et al., 2009). For this purpose, highly stabilizing or destabilizing chemical modifications are not frequently used in the guide strand seed region as they can dramatically reduce siRNA efficiency (Bramsen et al., 2009). It is indeed likely that most of the modification schemes proposed to moderately enhance siRNA potencies by modifying strand 3′-ends is indeed ensuring optimal thermodynamic asymmetry.

The thermo-stability profile of the internal part of the siRNA duplex seem also important as it influences rates of siRNA duplex unwinding during RISC loading and target RNA release; Design of a relatively loose siRNA duplex with an overall GC-content of 30–50% has been common practice (Wang et al., 2009a), yet more recently Gibbs free energy calculations by the nearest neighbor method has predicted efficient siRNAs and an energy cut-off ($\Delta G < -34.6$ kcal/mol) was introduced to reject too thermostable siRNAs (Ichihara et al., 2007). It remains, however, to be fully established if the preference for GC-poor siRNAs may rather indirectly reflect a higher accessibility of AU-rich target sites within the structured mRNA; in fact, target site accessibility is suggested to be more important to siRNA efficiency than GC-content per se (Chan et al., 2009).

A few studies have devised how the activity of too thermo-stable and therefore little potent siRNA, typically seen upon extensive LNA, 2′-OMe/2′-F modification, can be rescued by introducing counteracting modifications like destabilizing UNA modification (Laursen et al., 2010) or introducing a nicked passenger strand as in the so-called sisRNA design (Bramsen et al., 2007).
ENHANCING siRNA POTENCY BY siRNA OVERHANG MODIFICATION

Preferential guide strand loading into RISC can also be helped by modifying the canonical siRNA 2 nt 3′ overhangs, which are bound by the PAZ domain Ago during RISC loading (Ma et al., 2004). The PAZ domain was originally described to bind siRNA overhangs in a sequence unspecific manner (Lingel et al., 2004; Ma et al., 2004), yet siRNA overhang composition does influence their affinity for the Ago2 PAZ domain and siRNA potencies: particularly the UU overhang has high affinity for the PAZ domain but is concurrently easily dissociated from the PAZ domain upon strand cleavage (Lee et al., 2007). In agreement, superior silencing of siRNA with UU overhang as compared to AA, GG, and CC has been reported (Elbashir et al., 2001b). Hereby, differential use of UU in the guiding strand and GG, CC pairs in the passenger strand should ensure preferential loading of the guide strand into RISC. Also, the siRNA overhangs can, due to base stacking, contribute nearly the same to the thermodynamic stability as a regular base pair (O’Toole et al., 2005) and thereby help to direct siRNA strand selection by altering the siRNA thermodynamic asymmetry, a somewhat overlooked strategy. Finally, preferential guide strand loading into RISC can be helped by chemically modifying the siRNA 3′ overhangs hereby providing a sequence-independent, general strategy for enhancing siRNA performance. Modification types such as DNA, LNA, UNA, etc. that favor or disfavor strand selection during RISC loading have been identified and can be used in the guide and passenger strand, respectively, to enhance siRNA potency and specificity (Elbashir et al., 2001b; Dowler et al., 2006; Bramsen et al., 2009).

SEQUENCE-SPECIFIC siRNA DEGRADATION BY EXTRACELLULAR RIBONUCLEASES

Compared to ssRNA, dsRNAs are rather poor substrates for most RNases and siRNA degradation is highly sequence-dependent upon incubation in blood serum, a popular mimic of “extracellular” conditions in vivo (Choug et al., 2006; Haupenthal et al., 2006; Hong et al., 2010). Here siRNA degradation is mediated primarily by RNase A-like activities (Haupenthal et al., 2006, 2007; Turner et al., 2007) that, being pyrimidine-specific endonucleases, cleave dsRNA at specific dinucleotide motifs such as UpA, CpA, and UpG (Qiu et al., 1998; Sorrentino, 1998; Turner et al., 2007; Volkov et al., 2009). Recent efforts have characterized siRNA degradation products to identify particularly vulnerable sequence-motif and indeed degradation in serum occur at only few sites, primarily at UA and CA dinucleotides (Choug et al., 2006; Turner et al., 2007; Volkov et al., 2009). It is still not fully clear how the siRNA thermodynamic stability influences endonuclease resistance; seminal RNases are reported to recognize vulnerable single-stranded regions exposed from the duplex by thermal fluctuations predicting that thermo-stable siRNA would be more nuclease resistant. In accordance, thermodynamically “loose” regions within the siRNA duplex, which is deliberately introduced in the siRNA by design to ensure guide strand RISC loading, are reportedly more prone to nuclease attack than thermodynamically more stable regions (Haupenthal et al., 2006). In contrast, a comprehensive study found no general thermodynamic difference between the vulnerable regions and the remaining siRNA and that both strands were cleaved simultaneously (almost exclusively at UA and CA motifs) arguing against recognition of exposed single-stranded motifs (Hong et al., 2010). These discrepancies aside, avoidance or modification of UA and CA motifs within the duplex stem is an attractive strategy to enhance endonuclease resistance.

Notably, blunt-ended siRNA are reportedly more stable in sera than their canonical counterparts (Czauderna et al., 2003) leading to the suggestion that exo-nucleases are dominant mediators of siRNA degradation in serum (Soutschek et al., 2004). However, latter studies report little indications for high exonuclease activity in serum (Haupenthal et al., 2006; Turner et al., 2007) and propose that the siRNA 2 nt 3′ overhangs may reduce siRNA stability in serum by allowing ribo-endonucleases to dock on the siRNAs (Haupenthal et al., 2006). In any case, chemical modification of siRNA overhangs is a popular approach to slightly enhance siRNA nuclease resistance as described below.

DESIGNING NUCLEASE RESISTANT siRNAs BY CHEMICAL ENGINEERING

The general high susceptibility of single-stranded RNA to ribonuclease degradation (Tsui et al., 2002) and initial observations that unmodified siRNAs are subject to relatively fast serum degradation (Czauderna et al., 2003; Choug et al., 2006) suggested that siRNA would need chemical stabilization to succeed as a systemically applied RNA therapeutic. Indeed, the subsequent observation that chemical stabilization was essential for successful silencing by unformulated siRNAs following intravenous injection in mice only consolidated this point and made chemical stabilization a integral part of siRNA engineering. In essence, however, chemical stabilization is little needed for typical siRNA applications in cell culture where commercial transfection reagents will shield the siRNAs from serum RNases. In a therapeutic setting siRNA may also only need extensive chemical stabilization if exposed to extracellular environments such as the blood stream, digestive tract, lung, or skin, in particular if delivered unformulated, and modification strategies for formulated siRNAs need rather focus on reducing siRNA immunogenicity, off-targeting without jeopardizing silencing potency/duration. Still, chemical stabilization may enhance silencing duration (see Enhancing Silencing Duration) and application of naked, chemically modified siRNA is still a popular approach with both formulated and unformulated siRNAs currently undergoing pre- and clinical investigation (Schmidt, 2011).

INTRACELLULAR siRNA STABILITY

Small interfering RNAs are far more stable once inside the cell and silencing can last 30–90 days in slowly or non-dividing cells (Song et al., 2003; Bartlett and Davis, 2007); It is likely that some stability is gained upon incorporation into RNAi protein complexes such as RISC, however, double-stranded siRNAs are reported to be quite stable intracellular in contrast to their corresponding single strands (Rao et al., 2006). Still, the 3′ exonuclease Eri-1 (Kennedy et al., 2004; Takabatake et al., 2007) has been described as a key mediator of intracellular siRNA degradation and high doses of siRNA can enhance Eri-1 levels suggesting that the RNAi machinery may be controlled by a negative feedback mechanism (Hong et al., 2005; Bian et al., 2011).
ENHANCING siRNA NUCLEASE RESISTANCE BY CHEMICAL MODIFICATION

The most common route of non-specific degradation, which is also catalyzed by several nucleases, involves a nucleophilic attack of the ribose 2′-OH and hydrolysis of the interphosphate linkage via a 2′,3′-cyclic phosphate intermediate (Usher, 1969). Therefore, siRNA nuclease resistance is enhanced by modifying the ribose 2′-OH groups or the internucleotide phosphate linkage. As extensive chemical modification tends to reduce siRNA potencies the challenge is to identify modification schemes that balance stability and silencing potency in respect to the specific delivery strategy, e.g., siRNA formulation and delivery route.

With the assumption that more modifications would generate better serum stability, early efforts to prepare siRNA for naked systemic delivery aimed to maximize the number of modified positions within siRNA duplex. Especially, the combination of moderate phosphoromonothioate (PS) backbone modification with small, well-tolerated 2′ substitutions (2′-F, 2′-OMe, and 2′-H) or even fully modified siRNAs have often created highly stable siRNA for applications in vivo (Soutschek et al., 2004; Allerson et al., 2005; Morrissey et al., 2005b; Zimmermann et al., 2006; Blidner et al., 2007; Nishina et al., 2008). In some cases, modification schemes can be very complex; a successful example is a siRNA having a passenger strand with 2′-F substitutions on all pyrimidine positions, DNA in all purine positions, 5′ and 3′-inverted abasic end caps and a guide strand with 2′-F substitutions in all pyrimidine positions, 2′-OMe substitutions of all purines and a single PS modification at the 3′ terminal linkage that produced dose-dependent gene silencing upon intravenous injection in mice (Morrissey et al., 2005b). Extensively modified siRNA is still the norm for systemic administration and future commercial siRNA therapeutics may likely be fully modified siRNA harboring complex modification schemes, at least if not protected by formulation. Yet, for general siRNA design, complicated modification schemes hold the obvious pitfall of dramatically reducing siRNA functionality and siRNA sequence dependencies are not always fully understood. Also, researches may find the task of testing multiple heavily modified siRNAs to identify potent candidates for applications in vivo both technically and financially challenging.

The recent pinpointing of siRNA dinucleotides vulnerable to nuclease attack suggest that their selective chemical modification may represent a general strategy to greatly enhance siRNA nuclease resistance while preserving siRNA potency (Turner et al., 2007; Armstrong et al., 2008; Volkov et al., 2009). Typically, the well-tolerated 2′-OMe and 2′-F modifications are used within the duplex stem to modify UA and CA motifs and can dramatically improve nuclease resistance with little impact on siRNA potency (Turner et al., 2007; Armstrong et al., 2008; Volkov et al., 2009; Hong et al., 2010). Also, as siRNA 3′ overhangs are stabilized by most modification types, these may well be chosen to simultaneously ensure preferential loading of the guide strand (see above), e.g., the LNA modification proposed by Bramsen et al. (2009) will simultaneously enhance stability and potency. Notably, UNA-modified overhangs were found to dramatically enhance the serum stability of otherwise unmodified siRNAs in mouse serum leading to successful gene silencing in vivo, whereas little difference in stability was seen in bovine serum (Laursen et al., 2010) likely reflecting species differences in RNase composition or serum preparation; As a note of caution, degradation of siRNAs is faster in human than mouse serum suggesting that future therapeutic application of unformulated siRNAs may prove more difficult in humans than in mouse models (Haupenthal et al., 2006).

Alternatively, siRNAs may be stabilized by moderately enhancing their local thermodynamic stability to minimize the accessibility of vulnerable sequence-motifs exposed by thermal fluctuations, e.g., the introduction of stabilizing LNA (Braasch et al., 2003; Grunwell et al., 2003; Elmén et al., 2005; Mook et al., 2007; Bramsen et al., 2009) or 4′ thiorybose (Dande et al., 2006) at selected positions within the duplex can enhance siRNA stability while generally preserving siRNA potency. Notably, siRNAs are designed to be thermodynamically asymmetric and hereby more "loose" in one duplex end hereby rendering it particular exposed to endonuclease attack, a problem that has been addressed by 2′-OMe modification of loose regions (Hoerter and Walter, 2007).

ENHANCING SILENCING DURATION

The transient nature of gene silencing by synthetic siRNA poses concerns for therapeutics as it will require repeated dosing at short intervals. Such transience is primarily due to the continuous dilution of the effective intracellular siRNA pool through cellular proliferation and degradation; in cultures of proliferating cells, silencing duration is most dependent on dilution through cell division and silencing normally persists for no more than 2–7 days whereas this period can be extended for several weeks in terminally differentiated non-dividing cells, such as macrophages, and up to 1 month in the slowly dividing CCD-1074Sk cells (Bartlett and Davis, 2007). Encouragingly, this implies that silencing duration may be much longer in a therapeutic setting where target cells usually are slowly or non-dividing and indeed long-lasting target inhibition in the livers of mice and non-human primates have been reported (Zimmermann et al., 2006).

SEQUENCE-DEPENDENT SILENCING DURATION

Small interfering RNA silencing duration appears to be sequence-dependent and does not necessarily correlate with initial silencing efficacy (Straps et al., 2010). The basis for such sequence-dependency remains unresolved but may reflect multiple factors such as the differences in intracellular stability of unbound siRNA, their affinity for RNAi pathway components, reaction kinetics and target (and off-target) levels (Arvey et al., 2010). Also, endogenous proteins that bind siRNA and dampen silencing activity, such as Eri-1 (Kennedy et al., 2004; Bian et al., 2011) and ADAR1 (Hong et al., 2005), may have sequence-dependent affinities for siRNAs. Notably, the expression of Eri-1 and ADAR1 are induced by high-doses of siRNA and may account for the observation that higher doses of siRNA in some instances had lower silencing duration than lower doses both in cell cultures and in mouse livers upon hydrodynamic injection (Hong et al., 2005; Bian et al., 2011).

ENHANCING siRNA SILENCING LONGEVITY BY CHEMICAL STABILIZATION

Many studies attribute the prolonged silencing duration of chemically modified siRNAs to their high nuclease resistance which
would ensure delivery of more intact siRNAs into the cell and subse-
quently stabilize the internalized siRNA pool available for RISC recruitment. Several of the stabilizing modifications mentioned above have also been reported to slightly enhance the duration of silencing using 2′-OMe (Collingwood et al., 2008; Volkov et al., 2009), F-ANA (Dowler et al., 2006), 2′-F (Chiu and Rana, 2003), or complex modification schemes (Morrisey et al., 2005b), whereas other studies do not find enhancement of silencing persistence upon chemical stabilization (Layzer et al., 2004). A direct comparison of stabilized and unmodified siRNAs delivered by several different methods in vitro and in vivo have suggested that the benef
effects of chemical stabilization arise during siRNA delivery prior to cellular internalization and that stabilization does not signifi-
cantly enhance silencing magnitude or persistence once siRNA are
located in the cytoplasm (Bartlett and Davis, 2007). Still, Taka-
critical benefit may not have provided sufficient stability to
significantly enhance silencing persistence. In agreement, Volkov
et al. (2009) reported that prolonged silencing could only be iden-
tified in cell culture when all vulnerable dinucleotide motif were
2′-OMe-modified within the siRNA.

siRNA RECRUITMENT AND SILENCING DURATION
Notably, the industry-standard DNA overhangs, typically dTdT,
has been reported to significantly reduce silencing duration irre-
respectively of the siRNA sequence (Strapps et al., 2010) and it is
tempting to speculate that the reported sixfold higher affinity of
dTdT-siRNA for Ago2 (Maiti et al., 2011) may in fact reduce silenc-
ing duration as siRNAs are faster recruited and turned over than lower affinity siRNAs. In accordance with this, rates for siRNA-
RISC complex formation is two times slower for blunt siRNAs
compar
to canonical siRNA, whereas silencing persistence is
enhanced (Ghosh et al., 2009). Also, the dumbbell siRNA design
(Abe et al., 2007), which encompasses a 23-bp stem and 9-nt loops
at both ends, exhibits a prolonged silencing persistence poten-
tially because Dicer only very slowly processes RNA dumbbells
into siRNA species (Abe et al., 2011).

REDUCING siRNA IMMUNOGENICITY BY CHEMICAL MODIFICATION
The original observation that synthetic 21-mer siRNA can trig-
ger sequence-specific mRNA degradation without apparent side-
effects in human cell cultures promised synthetic siRNA to bedrock
efficient and safe RNA therapeutics (Elbashir et al., 2001a). This observation was especially appreciated as the intro-
duction of long dsRNA, a gene silencing strategy employed in
popular non-mammalian systems, had been precluded in mam-
mals by the induction of innate immune responses leading to
pro-inflammatory cytokine production and ultimately cell death
(Minks et al., 1979). It is becoming increasingly clear, however,
that unmodified synthetic siRNA can be triggers of innate immune
responses depending on their structure, sequence, target cell type,
entry route, formulation reagent used and concentration, despite
their structural mimicry of endogenous siRNA/miRNA species
(Sledz et al., 2003; Hornung et al., 2005; Judge et al., 2005; Sioud,
2005; Reynolds et al., 2006). A variety of proteins, commonly
referred to as pattern recognition receptors (PRRs), act as cellular
sensors of exogenous RNA both extra- and intracellularly, where
they monitor predefined hallmarks of foreign, typically viral, RNA
such as length, 5′-end triphosphates, sequence composition, heli-
cal structure, and end-groups (Sioud, 2009). Most important to
siRNA recognition are three members of the transmembrane Toll-
like Receptor (TLR) family, namely TLR3 and TLR7/8, which
recognize double or single-stranded RNA, respectively, primar-
ily in immune cells and endo and epithelial linings of the body, as
described below.

DETECTION OF siRNAs BY TLR3
TLR3 senses the length of exogenous dsRNA (Alexopoulou et al.,
2001) on the cell surface and in endosomes of dendritic cells,
epi-, and endothelial linings (Cario and Podolsky, 2006; Kleinman
et al., 2008; Lim et al., 2009; Zimmer et al., 2011; Taura et al.,
2012) and consequently in many primary cells and popular cell
lines (Kariko et al., 2004; Reynolds et al., 2006). Twenty-three
mer siRNAs were early reported to trigger low-level immuno-
genicity through TLR3 in HEK293 cells (Kariko et al., 2004), an
effect that was subsequently found highly duplex length and cell
type specific; Reynolds et al. (2006) found that canonical 21-mer
siRNAs did not trigger innate immune responses in human cell
lines whereas longer siRNAs (23–33 mer) led to concentra-
tion-dependent, sequence-independent and presumably TLR3 medi-
ated interferon-responses in some cell lines (DU145, HeLa S3, and
MCF-7), but not in other cell lines (HeLa and HeK293 cells). In
agreement, a very comprehensive study shows that longer DsiR-
NAs are indeed more immunogenic than 21-mer siRNAs both
in vitro and in vivo (Foster et al., 2012) and that such dsRNA
designs are therefore not suited for siRNA therapeutics in a chem-
ically non-modified form. Notably, sequence-independent activa-
tion of surface-bound TLR3 on retinal pigmented epithelial cells
has been reported in a murine choroidal neovascularization model
upon intraretinal injection of naked 21-mer siRNAs (Kleinman
et al., 2008). Also, shorter 19-mer siRNA designs did not trigger
TLR3 activation, observations that were subsequently confirmed
in other mouse models (Cho et al., 2009; Berge et al., 2010).

PREVENTING ACTIVATION OF TLR3
The activation of murine TLR3 by unformulated 21-mer siRNA has raised natural concerns for future siRNA therapeutics. How-
ever, similar effects may not apply to human cells; Weber et al.
(2012) found that none of the tested TLR3 expressing human
cell lines were responsive to unformulated, naked 21-mer siRNA,
which may be due to sequence differences in the RNA binding
ectodomain among species (Ranjith-Kumar et al., 2007). Still,
researches may choose to use only 19-mer siRNA design that seem
non-immunogenic and accept the slightly reduced potency of this
siRNA platform or may instead choose to chemically modify the
21-mer siRNA structure to make it unrecognizable to TLR3, a task
that is currently ongoing. In this regard, activation of PKR, a cyto-
plasmic dsRNA sensor, has been abrogated in HeLa cells by site-
specific introduction of purine N2-benzyl modifications in the
siRNA passenger strand (Puthenveetil et al., 2006). Also, disrupting
the structure of a 47-bp dsRNA by introduction of GU wobble
base pairs or introduction of 2′-deoxyuridinyl, 4-thiouridinyl, and 2-thiouridinyl (s2U) reduced PKR activation whereas 2′-F and PS did not (Nallagatla and Bevilacqua, 2008). Such abrogation of PKR activation suggests that chemical modification may similarly help reduce potential TLR3 activation by 21-mer siRNA.

**DETECTION OF siRNA BY ENDOSONAL TLR7/8**

Small interfering RNAs can, upon internalization by endocytosis, be recognized by TLRs 7 and 8 (TLR7/8), which are transmembrane receptors exclusively found in the endosomes in different leukocyte subsets; TLR7 is mainly expressed in plasmacytoid dendritic cells (pDCs) and B cells, whereas TLR8 is expressed in monocyte-derived DCs (mDCs), monocytes, macrophages, or regulatory T cells (Hornung et al., 2002; Heil et al., 2004; Kokkinopoulos et al., 2005). TLR7/8 are reported to recognize specific single-stranded RNA motifs, which may be exposed from the siRNA duplex upon random thermal fluctuations. A number of immunostimulatory GU- or U-rich motifs can trigger TLR7 activation such as GUCCUCUCAA (Judge et al., 2005), UGGU (Sioud, 2006), UGCC (Fedorov et al., 2006), UCA (Jurk et al., 2011), and GU (Diebold et al., 2004; Heil et al., 2004) whereas AU-rich motif primarily stimulate TLR8 (Forsbach et al., 2008). Collectively, such motifs all agree with the consensus that multiple uridines in close proximity are both necessary and sufficient for TLR7 stimulation (Diebold et al., 2006) whereas the exact sequence requirement and positional effects within the siRNA are not fully understood (Gantier et al., 2008; Goodchild et al., 2009); In fact, a single uridine may be sufficient to activate an immune response in a 5′-UCA-3′ sequence context whereas other uridine positions are non-immunogenic (Jurk et al., 2011).

**ABROGATING TLR7/8 ACTIVATION BY CHEMICAL MODIFICATION**

Activation of endosomal TLR7/8 is currently considered the major source of siRNA immunogenicity in vivo (Hornung et al., 2005; Judge et al., 2005; Sioud, 2006; Cekaite et al., 2007; Robbins et al., 2008; Zamanian-Daryoush et al., 2008), which suggest that most siRNA immunogenicity may be avoided in human cells either by using delivery method that prevents siRNA endosomal retention (Sioud, 2005; Inaba et al., 2012) or by rendering siRNAs unrecognizable to TLR7/8 by chemical modification. The latter has been achieved by modifying the specific immunogenic sequences within the siRNA duplex; typically, small 2′ OH substitution have been employed, such as 2′-F, 2′-H, and 2′-OMe, as these can effectively abrogate TLR activity while generally preserving silencing activity even upon extensive modification. Most efforts have focused on modifying U or U-rich regions within either or both strands of the siRNA (Heil et al., 2004; Diebold et al., 2006) as uridine residues are critical for siRNA activation of TLR7/8 (Heil et al., 2004; Hornung et al., 2005; Diebold et al., 2006; Eberle et al., 2008) and a significant correlation between the U count and siRNA immunogenicity has been suggested (Diebold et al., 2006; Goodchild et al., 2009). In fact, the rather commonly used UU overhangs can, in some cases, contribute to the activation of TLR7/8 (Goodchild et al., 2009). Modification of siRNA uridines with either 2′-F or 2′-OMe (Cekaite et al., 2007) or deoxynucleotide residues (Eberle et al., 2008) has been suggested as a general strategy to abrogate siRNA immunogenicity while preserving siRNA potency; In this regard, 2′-F is slightly less efficient in reducing siRNA immunogenicity than, e.g., 2′-OMe, which conversely is more likely to reduce siRNA potency (Prakash et al., 2005; Shin et al., 2007; Fucini et al., 2012). Notably, not only uridine, but also guanidine and adenosine modification have been reported to reduce siRNA immunogenicity, at least when a certain threshold of modification is met, whereas cytidine modifications have no effect (Hornung et al., 2005; Kariko et al., 2005; Morrissey et al., 2005b; Judge et al., 2006; Eberle et al., 2008; Fucini et al., 2012; Ocampo et al., 2012). Recently, selective adenosine modification, especially by 2′-OMe, has been recommended as it was found to most consistently reduce immunogenicity upon both 2′-OMe and 2′-F modification of different sequences (Robbins et al., 2007; Fucini et al., 2012). Encouragingly, 2′-OMe is particular potent in reducing siRNA immunogenicity (Robbins et al., 2007; Fucini et al., 2012) and alternating 2′-OMe modification of the passenger strand has been proposed as a universal approach to avoid TLR7 activation as it does not reduce guide strand potency (Hamm et al., 2009). This special property of 2′-OMe-modified RNA may reflect it being a potent antagonist of TLR7 activation: even single 2′-OMe modification can reduce immunogenicity in vitro and in vivo (Tluk et al., 2009) and 2′-OMe-modified oligoehes can reduce the immunogenicity of other RNAs in trans upon co-transfection (Robbins et al., 2007).

The strength of hybridization between the siRNA strands has been suggested to correlate negatively with immunogenicity; interpersed CG or GC clamps may inhibit TLR7/8 activation by increasing siRNA thermostability and thereby impair the exposure of stimulatory single-stranded RNA upon breathing (Goodchild et al., 2009). Indeed, enhancing siRNA thermostability, e.g., by moderate LNA modification even of the strand opposing the putative immunogenic motif (Hornung et al., 2005; Goodchild et al., 2009; Schyth et al., 2012), may reduce siRNA immunogenicity by making the single-stranded immunogenic sequence-motif inaccessible to TLR7/8 recognition.

Other modifications types have also been shown to reduce TLR7/8 activation such as backbone PS modifications (Jurk et al., 2011) and base modifications including 5-methylcytidine (m5C), 5-methyluracil (m5U), N6-methyladenosine (m6A), s2U, or pseudouridine (Kariko et al., 2005) but are not widely used due to the success of other modification types, particularly 2′-OMe.

**SENSORS OF CYTOPLASMIC siRNA**

Cytoplasmic siRNAs, originating from endosomal release or direct cytoplasmic transfection, are monitored by a number of cytoplasmic PRRs that, similarly to the TLRs, respond to predefined RNA characteristics. A prominent sensor of dsRNA length is the dsRNA- binding protein kinase R (PKR) that was originally described to sequence-independently act on dsRNA longer than 30 bp for regulation of cytokine expression in most cells types (Manche et al., 1992). Later studies demonstrated that only 17 bp dsRNA could activate PKR signal (Nanduri et al., 1998) and indeed modest PKR activation by 21-mer siRNAs has been reported in, e.g., microglial N9 (Zhang et al., 2006), T98G (Slezd et al., 2003; Marques et al., 2006; Puthenveetil et al., 2006), HeLa (Puthenveetil et al., 2006), MCF-7 (Armstrong et al., 2008), and HepG2.2.15 cells (Han et al., 2011). RIG-I is another prominent sensor of cytoplasmic
dsRNA that can recognize dsRNA as small as 25bp and 5’-end triphosphates in a sequence-independent manner (Marques et al., 2006; Takahasi et al., 2008). The canonical 21-mer siRNA design having two 2 nt 3’ overhangs is tolerated, yet blunt 21–27-mer siRNA can activate RIG-I (Marques et al., 2006). Also, melanoma differentiation-associated gene 5 (Md5) has been reported to respond to siRNA (Kang et al., 2002).

The impact of modest cytoplasmic PRR activation needs to be studied further, a task that is complicated by the complex interplay of signaling pathways during innate immune responses. Notably, direct cytoplasmic delivery of siRNA by electroporation into human blood cells abrogated the siRNA immunogenicity observed when delivering identical siRNAs via endosomes using lipids, which suggests that synthetic siRNAs are rather detected in vivo. TL-mediated responses during application. Therefore researches tend to focus more on reducing the potent by TLRs than cytoplasmic sensors in immune cells (Sioud, 2005). Off-target effects can lead to cellular toxicity (Fedorov et al., 2006), misinterpreta-

METHODOLOGY

REDDUCING siRNA OFF-TARGET EFFECTS BY CHEMICAL MODIFICATION

The high sequence specificity of siRNA action was immediately praised as a major benefit of RNAi-based gene silencing. Indeed, The RISC/Ago2-mediated cleavage of target RNAs by a matching siRNA is highly sequence-specific allowing only few mismatches, particularly at siRNA terminal ends (Du et al., 2005; Dahlgren et al., 2008). Hereby cleavage of unintended targets can simply be avoided during siRNA design by BLASTing candidate sequences against the relevant transcriptome. Still, siRNA significantly influence the target cell transcriptome in a sequence and concentration-dependent manner by triggering modest and unintended silencing of hundreds of endogenous genes (Doench et al., 2003; Jackson et al., 2003; Lim et al., 2003; Birmingham et al., 2006). Such so-called off-target effects may immediately remain unnoticed, but can lead to cellular toxicity (Fedorov et al., 2006), misinterpreta-

Reduction off-target effects reflect the shared handling of siRNA and miRNA by the RNAi pathway, which inherently enable siRNAs to behave as miRNAs (Doench et al., 2003). Hereby siRNA off-targeting is primarily mediated by the interaction between the seed region of the RISC-associated guide strand (positions 2–7/8 counting from the 5’-end) and complementary sequences in mRNA 3’-UTRs (Lin et al., 2005; Birmingham et al., 2006) leading to translational inhibition and mRNA destabilization rather than mRNA cleavage by Ago2 (Doench and Sharp, 2004; Wu et al., 2006; Back et al., 2008; Guo et al., 2010). Although off-target effects are somewhat predictable and may be minimized by in silico analysis (similar to miRNA target prediction) they cannot be fully avoided and remain an inherent feature of unmodified siRNAs (Doench et al., 2003; Jackson et al., 2006b). Off-target effects can be minimized by using the lowest possible dose of siRNAs sufficient for efficient target KD (Jackson et al., 2003, 2006b) or by using siRNA pools directed against multiple target sites in the same mRNA to reduce the contribution of individual siRNAs to off-targeting (Myers and Ferrell, 2005; Myers et al., 2006). Yet, the competition between co-transfected siRNAs for incorporation into RISC complicates this latter strategy (Castanotto et al., 2007). Furthermore, as off-targeting can be mediated by both strands of the duplex (Wei et al., 2009), designing siRNA with optimal thermodynamic asymmetry will ensure preferential guide strand uptake into RISC and reduce passenger strand off-targeting.

A more indirect type off-targeting comes from the competition between exogenous siRNA and endogenous miRNAs for RISC proteins; siRNA (and miRNAs) have different affinities for RISC (Koller et al., 2006; Castanotto et al., 2007; Vickers et al., 2007), which is reportedly determined by the siRNA seed sequence (Yoo et al., 2008) and siRNAs can effectively compete out endoge-

MINIMIZING PASSENGER STRAND OFF-TARGETING BY CHEMICAL MODIFICATION

Owing to the structural symmetry of the canonical siRNA, both strands may potentially contribute to off-targeting (Wei et al., 2009), a matter that has been resolved by chemical modification. For siRNAs designed with insufficient thermodynamic asymmetry between duplex ends, selective unwinding of the siRNA from the 5’-end of the guide strand can be favored by introducing additional asymmetric thermostability by chemical modification identical to those that aim to enhance siRNA potency through selective guide strand loading. Similarly, asymmetric chemical modification of siRNA overhangs can disfavor passenger strand selection during RISC loading to enhance silencing specificity (see Designing Potent siRNAs by Chemical Engineering). Chemical modification may also be employed to fully prevent loading of the passenger strand: The 5’-phosphate of the passenger strand, required for strand function (Nykamen et al., 2001), may be chemically blocked, e.g., by 5’-OMe modification to prevent binding the AGO MID domain (Chen et al., 2008). Similarly, a single UNA modification at the 5’-terminus of the passenger strand can reduce unspecific passenger strand activity (Vaish et al., 2011).

A radical approach to prevent passenger strand off-targeting is to use alternative siRNA designs; aRNAs or asiRNAs harbour shortened passenger strands which cannot be efficiently loaded into RISC (Chu and Rana, 2008; Sun et al., 2008; Chang et al., 2009) whereas the three stranded ssiiRNA design renders the passen-

Reducing off-target effects by modifying the guide strand seed region

The initial interaction between the siRNA guide strand (or miRNA) and target RNA is mediated by the seed region exposed
by RISC (Wang et al., 2008). Therefore, mismatches in or chemical modification of this region have a severe effect on the miRNA-like interference that often only relies on seed matching (Birmingham et al., 2006) whereas fully matched siRNAs can usually accommodate a single mismatch at selected seed positions without a substantial loss of silencing efficacy (Du et al., 2005; Dahlgren et al., 2008). Therefore position-specific modifications in the seed region of the guide strand have been screened to reduce the siRNA off-targeting potential while preserving siRNA effects through target cleavage. Jackson et al. (2006a) demonstrated that 2′-OMe modification can site-specifically reduce off-targeting when positioned at guide strand position 2 without severe reductions in siRNA potencies. A similar screen reported that substituting the entire guide strand seed region, e.g., positions 1–8 with DNA could also reduce off-targeting although the effects seemed more sequence-specific (Ui-Tei et al., 2008). Recently, we showed that incorporation of the strongly destabilizing UNA modification at position 7 very potently eliminated off-target effects with minimal negative impact on siRNA efficiency in three different siRNA tested (Bramsen et al., 2010), a result subsequently confirmed by others (Vaish et al., 2011). Although these finding greatly enhance the therapeutic potential of siRNAs, it remains to be fully explored how applicable these modification principles are translated to RNAi in vivo.

ALTERNATIVE MEANS TO REDUCE OFF-TARGETING

Off-targeting by siRNA may also be reduced by insuring that siRNAs are primarily loaded into RISC complexes harboring the cleavage-competent Ago2 in contrast to Ago1, -3, or -4-containing RISC, which would not allow target cleavage, but merely miRNA-like effects. Synthetic siRNA duplexes interact with all Ago proteins, yet the non-catalytic Ago1, -3, and -4 can be selectively inhibited by stabilizing siRNA with LNA hereby leading to increased silencing activity via Ago2-RISC and potentially less off-targeting (Petri et al., 2011). Also, the perturbance of endogenous miRNA pathways upon siRNA transfection may quite naturally be minimized by using a minimal amount of siRNAs (Khan et al., 2009). Alternatively, chemical modification has been shown to influence siRNA competitive powers (Yoo et al., 2008) and chemical modification schemes that ensure sufficient silencing with a minimum of miRNA pathway perturbance are likely to be established soon.

FINAL REMARKS: BUILDING AND MAKING GOOD USE OF CHEMICALLY OPTIMIZED siRNAs

There is little doubt that chemical engineering can bring siRNAs closer to clinical success and, as explored throughout this text, it is now fairly well established how chemical modification can enhance siRNA potency, nuclease resistance, and reduce siRNA immunogenicity and off-targeting. However, the difficulty of efficient and targeted siRNA delivery in vivo represents the major bottleneck for broader clinical application and concurrently hampers the evaluation and further chemical refinement of siRNA performance and it seems that more immediate clinical success is pivotal to maintaining the high momentum in siRNA drug development. In this regard, implementation of promising local delivery systems by smaller RNAi R&D companies may prove most promising, while universal systemic delivery strategies, commercialized by major Pharma industries, are more distant goals.

Very extensively or fully modified siRNAs have typically been most successful in vivo during early development of chemically modified siRNAs (Soutschek et al., 2004) but may also be inhibitory to rapid advances into clinical testing due to higher cost and availability of the modified nucleotides. However, the initial reports from clinical application suggests that high modification levels may not always be needed, even for unformulated siRNAs (Leachman et al., 2010), and the concurrent use of protective siRNA delivery vehicles predicts that siRNA modification levels may be kept relatively low. While awaiting more clinical success of siRNA therapeutics our knowledge of natural gene silencing pathways is expanding and particularly the regulation and deregulation of miRNAs expression in human diseases hold diagnostic, prognostic and therapeutic value. Strategies for replenishing reduced or lost miRNA expression in human disease by introducing miRNA mimics or inhibiting aberrantly expressed miRNAs via synthetic anti-miRs is currently gaining momentum (Bader et al., 2010). As synthetic siRNA and miRNA mimic are practically identical, the huge arsenal of chemical modification schemes developed for siRNAs will greatly aid the fast development of synthetic miRNA therapeutics in the years to come.

A QUICK GUIDE TO CHEMICAL siRNA DESIGN

In Figure 4 we summarize our own general strategy for siRNA design and modification, which aim to keep modification levels low. Whereas this may serve as an inspiration to fellow siRNA researchers, experimental validation of function in vivo is still needed and one may still consider utilizing more extensive and well-characterized modification schemes (as described in the text above).

We recommend that siRNA should be designed by first selecting the desired siRNA type; here the canonical 21-mer siRNA has been extensively tested and has produced potent and safe gene silencing in vivo although the concerning TLR3 activation observed in mice may need further evaluation in human cells. The primary siRNA sequence should be chosen to target highly accessible regions within the target RNA as the siRNA thermo-stability profile can subsequently be tweaked by chemical modification, whereas no modification types have been reported to improve siRNA performance on poorly accessible target. To optimize specificity, siRNA should not share extensive sequence complementarity to non-intended targets and off-targets base-pairing to siRNA positions 2–16 should preferably be avoided. siRNAs should be designed to be thermodynamically asymmetric, preferably by primary sequence selection of A/U base-pairing at positions 1–2 and G/C base-pairing at position 19 of the guide strand. To introduce additional thermodynamic asymmetry, destabilizing modification can be introduced in the passenger 3′-end or stabilizing modification in the 5′-end, if needed. Similarly, asymmetric overhang modification can affect strand selection to enhance siRNA potency and specificity and modestly enhance nuclease resistance, whereas dTdT overhangs should be avoided as they reduce silencing longevity. Also, the incorporation of the passenger strand into RISC can be fully avoided by blocking its 5′-phosphate group. Importantly, miRNA-like off-targeting is best
Choose siRNA type (see figure 2)
The canonical 21mer siRNA design is recommended as it has been extensively tested and has an excellent track record.

Choose highly accessible target sites
Target site accessibility can be predicted by freely available software such as the Vienna RNA Package.

Choose “naturally” thermodynamically asymmetric targets
Choose A/U base pairs at the 5’ terminal 1-2 positions of the guide stand and GC base pairs in its 3’ end. Avoid GC-rich seeds and overall high GC content.

Tweak siRNA thermodynamic asymmetry by chemical engineering
Introduce stabilizing modification in the guide strand duplex 3’ end / passenger strand duplex 5’ end or destabilizing modification in passenger duplex 3’ end.

Optimize strand selection by 3’ overhang modification
Use favored and disfavored overhang modifications in guide and passenger strand, respectively. dTdT (DNA) overhangs can reduce silencing longevity.

Prevent passenger activity by chemical modification
Blocking the passenger strand 5’ OH group by modification abrogates its utilization by RISC. Alternatively, a two strand passenger design can be used (sisiRNA).

Reduce guide strand off-targeting by UNA-modification
Introduce UNA at guide strand position 7. Alternatively 2’OMe at position 2 or DNA at position 1-8.

Enhance nuclease resistance by modifying dinucleotide motifs
Modifying nuclease sensitive AU and CA motifs by 2’OMe or 2’F can significantly enhance stability. Extreme stability may be sought by combining full, alternating or extensive 2’-F and 2’-OMe modification combined with moderate PS or 4’S modification, but may reduce siRNA potency.

Reduce immunogenicity by 2’OMe modification
Activation of human TLR3 by 21mer siRNA needs further investigation. Even low levels of 2’OMe modification, which is typically used to enhance siRNA stability (see above), may be sufficient to avoid TLR7/8 activation. Otherwise modification of passenger strand U’s by 2’OMe and guide strand U’s by 2’F is an alternative.

Choose highly accessible target sites
Target site accessibility can be predicted by freely available software such as the Vienna RNA Package.

Choose “naturally” thermodynamically asymmetric targets
Choose A/U base pairs at the 5’ terminal 1-2 positions of the guide stand and GC base pairs in its 3’ end. Avoid GC-rich seeds and overall high GC content.

Tweak siRNA thermodynamic asymmetry by chemical engineering
Introduce stabilizing modification in the guide strand duplex 3’ end / passenger strand duplex 5’ end or destabilizing modification in passenger duplex 3’ end.

Optimize strand selection by 3’ overhang modification
Use favored and disfavored overhang modifications in guide and passenger strand, respectively. dTdT (DNA) overhangs can reduce silencing longevity.

Prevent passenger activity by chemical modification
Blocking the passenger strand 5’ OH group by modification abrogates its utilization by RISC. Alternatively, a two strand passenger design can be used (sisiRNA).

Reduce guide strand off-targeting by UNA-modification
Introduce UNA at guide strand position 7. Alternatively 2’OMe at position 2 or DNA at position 1-8.

Enhance nuclease resistance by modifying dinucleotide motifs
Modifying nuclease sensitive AU and CA motifs by 2’OMe or 2’F can significantly enhance stability. Extreme stability may be sought by combining full, alternating or extensive 2’-F and 2’-OMe modification combined with moderate PS or 4’S modification, but may reduce siRNA potency.

Reduce immunogenicity by 2’OMe modification
Activation of human TLR3 by 21mer siRNA needs further investigation. Even low levels of 2’OMe modification, which is typically used to enhance siRNA stability (see above), may be sufficient to avoid TLR7/8 activation. Otherwise modification of passenger strand U’s by 2’OMe and guide strand U’s by 2’F is an alternative.
modification may fully abrogate TLR7/8 responses, nuclear sensitivities (primarily UA and CA) may be modified by 2'-OME in the passenger strand to enhance siRNA stability while abrogating immunogenicity. As 2'-OMe may not well-tolerated in the guide strand seed, 2'-F modification should instead be used at nuclease sensitive sites in this region. Alternatively, both nuclease resistance and immunogenicity may be addressable by slightly enhancing siRNA thermodynamic stability, e.g., by LNA modifications.

ACKNOWLEDGMENTS

The preparation and publication of this manuscript was funded by the The Lundbeck Foundation in support of the LUNA Nanomedicine Center, Denmark.
Chu, Y. L., and Rana, T. M. (2002). RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10, 549–561.

Chu, Y. L., and Rana, T. M. (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034–1048.

Cho, W. G., Albuquerque, R. J., Klein- man, M. E., Tarollo, V., Greco, A., Nozaki, M., Green, G. M., Baffi, J. Z., Ambati, B. K., De Falco, M., Alexander, D. S., Brunetti, A., De Falco, S., and Ambati, J. (2009). Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc. Natl. Acad. Sci. U. S. A. 106, 7137–7142.

Choung, S., Kim, Y. J., Kim, S., Park, H. O., and Choi, Y. C. (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919–927.

Chu, C. Y., and Rana, T. M. (2008). Potent RNAi by short RNA triggers. RNA 14, 1714–1719.

Cirak, S., Archevache-Gomez, V., Gugliiermi, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., Dickson, G., Wood, M. J., Wilson, S. D., Straub, V., Kole, R., Shrewsbury, S. B., Sewry, C., Morgan, J. E., Bushby, K., and Muntoni, F. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595–605.

Collignon, M. A., Rose, S. D., Huang, L., Hillier, C., Armaragouii, M., Wiger, M. T., Soifer, H. S., Rossi, J. J., and Behlke, M. A. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18, 187–200.

Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Prong, G. J., Giese, K., and Kaufmann, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705–2716.

Dahlgren, C., Zhang, H. Y., Du, Q., Grahn, M., Norstedt, G., Wahlestedt, C., and Liang, Z. (2008). Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res. 36, e53.

Dande, P., Prakash, T. P., Siouti, N., Gaus, H., Jarres, R., Berdea, A., Swazy, E. E., Giffrey, R. H., and Bhat, B. (2006). Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclelease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem. 49, 1624–1634.

Davidson, B. L., and McCray, P. B. Jr. (2011). Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329–340.

Davis, M. E., Zuckerman, J. E., Choi, C. H., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Hede1, J. D., and Ribas, A. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070.

Deleagey, G. F., Watts, J. K., Alain, T., Robert, F., Kalota, A., Ashwarya, V., Pellerier, J., Gevirtz, A. M., Sonenberg, N., and Damha, M. I. (2010). Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res. 38, 4547–4557.

DeVincenzo, J., Cehelsky, J. E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., Nechev, L., Murugaiyah, V., Van Vliet, A., Vaishnaw, A. K., and Meyers, R. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-ASV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77, 225–231.

Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., and Tschil, T. (2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.

Elbashir, S. M., Martinez, J., Patanekowska, A., Lendeckel, W., and Tuschl, T. (2001b). Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20, 6877–6888.

Elmen, J., Lindnow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Strauss, E., and Kauppinen, S. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899.

Elmen, J., Thonborg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Orrum, H., Koch, T., and Wahlestedt, C. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439–447.

Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpi- low, J., Robinson, K., Leake, D., Marshall, W. S., and Khorovor, A. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12, 1188–1190.

Fiene, S., Xu, D., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811.

Fisher, M., Abramow, M., Van Aerschot, A., Zoenszen, J., Dixit, V., Juliano, R. L., and Heredewin, P. (2008). Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur. J. Pharmacol. 606, 38–44.

Fisher, M., Abramow, M., Van Aers- chot, A., Xu, D., Juliano, R. L., and Heredewin, P. (2007). Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res. 35, 1064–1074.

Forsbach, A., Nemorin, J. G., Montino, C., Muller, C., Samudowitz, U., Vic- ari, A. P., Jurk, M., Mutwiri, G. K., Krieg, A. M., Liford, G. B., and Vollmer, I. (2008). Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180, 3729–3738.

Foster, D. J., Barro, S., Duncan, R., Shaikh, S., Cantley, W., Dell, A., Bulgakova, E., O’Shea, J., Taneja, N., Kuchimanchi, S., Sherrill, C. B., Akinc, A., Hinkle, G., Seita, White, A. C., Pang, B., Charisse, K., Meyers, R., Manoharan, M., and Elbashir, S. M. (2012). Comprehensive evaluation of canonical versus dicer-substrate siRNA in vitro and in vivo. RNA 18, 557–568.

Freier, S. M., and Altmann, K. H. (1997). The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA/RNA duplexes. Nucleic Acids Res. 25, 4442–4443.

Fucini, R. V., Hartingsman, H., Li, Peng, D., Flanagan, W. M., and Willingham, A. T. (2012). Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther. 22, 205–210.

Gantier, M. P., Toon, S., Behlke, M. A., Xu, D., Phipps, S., Foster, P. S., and Williams, B. R. (2008). TL7R is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol. 181, 2117–2124.

Gao, S., Dagnaus-Hansen, F., Nielsen, E. J., Wengel, J., Besenbacher, F., Howard, K. A., and Kjems, J. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225–1233.

Ge, Q., Dallas, A., Ilves, H., Shoreenstein, J., Behlke, M. A., and Johnston, B. H. (2009a). Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short siRNAs. RNA 15, 118–130.

Ge, Q., Ilves, H., Dallas, A., Kummar, P., Shoreenstein, J., Kazarov, S. A., and
Bramsen and Kjems Chemical siRNA

Gore, K. R., Nawale, G. N., Harikrishna, S., Z. Glud, S., Bramsen, J. B., Dagnaes-Hansen, A., Wyszko, E., Bieber, J. H. (2009b). Minimal overhangs against blunt-ended siRNAs. *BMC Genomics* 10, doi:10.1186/1471-2164-10-51-S1

Glad, S. Z., Bramsen, J. B., Dagnaes-Hansen, F., Wengel, J., Howard, K. A., Nyengaard, J. R., and Kjems, J. (2009). Naked siRNA-mediated gene silencing of lung bronchoepithelial EGFP expression after intravenous administration. *Oligonucleotides* 19, 163–168.

Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G. M., Poidinger, M., Rivory, L. P., and Pasiora, T. (2009). Sequence determinants of innate immune activation by short interfering RNAs. *BMC Immunol.* 10, doi:10.1186/1471-2172-10-40

Gorr, K. R., Nawale, G. N., Harikrishna, S., Chittoor, V. G., Pandey, S. K., Hobartner, C., Patankar, S., and Piiper, A. (2007). RNA chemical modifications at the 3′-ends of siRNAs. *Antisense Nucleic Acid Drug Des.* 12, 301–309.

Hamm, S., Lutz, E., Hangel, D., Muller, T., Yu, P., Golenbock, D. A., Wasser, T., Wagner, H., and Bauer, S. (2009). Alternating 2′-O ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TRl7 antagonist. *Immunobiology* 215, 559–569.

Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R., and Hannon, G. J. (2001). Argonaute2, a link between genetic and biochemical analyses of RNAi. *Science* 291, 1146–1150.

Han, Q., Zhang, C., Zhang, J., and Tian, Z. (2011). Involvement of activation of PKR in HBs siRNA-mediated innate immune effects on HBV inhibition. *PLoS ONE* 6, e27931. doi:10.1371/journal.pone.0027931

Harborth, J., Elbashir, S. M., Vandenhurgh, K., Manniging, H., Scaringe, S. A., Weber, K., and Tuschl, T. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. *Antisense Nucleic Acid Drug Des.* 13, 83–105.

Haypalpital, I., Baehr, C., Kiemeyer, S., Zuevem, S., and Piiper, A. (2006). Inhibition of RNase A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. *Biochem. Pharmacol.* 71, 702–710

Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., and Bauer, S. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science* 303, 1526–1529.

Highleyman, L. (1998). FDA approves fomiviren, farniciclovir, and Thalidomide. Food and Drug Administration. *BETR*

Higuchi, Y., Kawakami, S., and Hashida, M. (2010). Strategies for in vivo delivery of siRNAs: recent progress. *Biodefugue* 4, 195–205.

Hoertter, J. A., and Walter, N. G. (2007). Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. *RNA* 13, 1888–1897.

Horige, R. I., Lebedev, A. V., Zon, G., Piroilo, K. E., Rait, A., Zhou, Q., Yu, W., and Chang, E. H. (2006). Chemically modified short interfering hybrids (siRNA/THBD): non-nominaloliposome delivery in vitro and in vivo for RNAi of HER-2. *Nuclei-

Hornung, H. (2004). Enhancement of RNAi activity by improved siRNA duplexes. *FEBS Lett.* 557, 193–198.

Horen, T., Amaragoussou, M., Babaei, E., and Pryde, H. (2003). Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAI pathway. *Nucleic Acids Res.* 31, 2401–2407.

Huang, J., Huang, Y., Li, Y., Zheng, J., Huang, H., Wei, N., Shan, Y., An, M., Zhang, H., Ji, J., Zhang, P., Xi, D., Qian, Z., and Liang, Z. (2010). Comprehensive analysis of sequence-specific stability of siRNA. *FASEB J.* 24, 4844–4855.

Hong, J., Qian, Z., Shen, S., Min, T., Tan, C., Xu, J., Zhao, Y., and Huang, W. (2005). High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNAI interference in the mouse. *Biochem. J.* 390, 675–679.

Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Hajo, P., Akira, S., Conzelmann, K. K., Schlee, M., Endres, S., and Hartmann, G. (2006). 5′-Triphosphate RNA is the ligand for RIG-I. *Science* 314, 994–997.

Hornung, V., Guenther-Biller, M., Bourquin, C., Ablaster, A., Schlee, M., Uematsu, S., Noronha, A., Manzanares, M., Akira, S., De Fougerolles, A., Endres, S., and Hartmann, G. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat. Med.* 11, 263–270.

Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., and Hartmann, G. (2002). Quantitative expression of toll-like receptor 1-10 RNAI in cellular subsets of human peripheral blood mononuclear cells and sensitivity to Cpg oligodeoxynucleotides. *J. Immunol.* 166, 4531–4537.

Hoshika, S., Minakawa, N., Kamiya, H., Harashima, H., and Matuda, A. (2005). RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. *FEBS Lett.* 579, 3115–3118.

Hoshika, S., Minakawa, N., Shionoya, A., Imada, K., Ogawa, N., and Matuda, A. (2007). Study of modification pattern-RNAI activity relationshions by using siRNAs modified with 4′-thioribonucleosides. *ChemBiochem* 8, 2133–2138.

Huusken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., Labow, M., Reinhardt, M., Natt, F., and Hall, J. (2005). Design of a genome-wide siRNA library using an artificial neural network. *Nat. Biotechnol.* 23, 995–1001.

Hutvagner, G., and Zamore, P. D. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. *Science* 297, 2056–2060.

Ichihara, M., Murakumo, Y., Masuda, A., Matsuura, T., Asai, N., Ijima, M., Ishida, M., Shinnm, J., Tatsuya, H., Qiao, S., Takahashi, M., and Ohno, K. (2007). Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. *Nucleic Acids Res.* 35, e123.

Inaba, S., Nagahara, S., Makita, N., Tarumi, Y., Ishitomi, T., Matsuos, S., Kodamakos, T., and Takei, Y. (2012). Ateolloccagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. *Mol. Ther.* 20, 356–366.

Iwase, R., Toyama, T., and Nishi- mori, K. (2007). Solid-phase synthesis of modified RNAs containing amide-linked oligornucleobases at their 3′-end and their application to siRNA. *Nucleosides Nucleotides Nucleic Acids* 26, 1451–1454.

Jackson, A. L., Barta, S. R., Schelter, I., Kobayashi, S. V., Burchard, J., Mao, M. L., Covet, G., and Lindsey, P. S. (2003). Expression profiling reveals off-target gene regulation by RNAI. *Nat. Biotechnol.* 21, 635–637.

Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Gao,
Bramsen and Kjems Chemical siRNA

Volchuk, A., Zatorski, A., Shum, D., Weissman, D. (2004). Exogenous synthetic siRNA mediates sequence-specific siRNA-dependent stimulation of the mammalian innate immune response by pre-miRNA. Nucleic Acids Res. 32, 4527–4535.

Lingel, A., Simon, B., Iazurralde, E., and Sattler, M. (2004). Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain. Nat. Struct. Mol. Biol. 11, 576–577.

Ma, J. B., Ye, K., and Patel, D. J. (2004). Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429, 318–322.

Matsi, M., Nauwelaerts, K., Lescinier, E., and Heredewijn, P. (2011). Structural and binding study of modified siRNAs with the Argonaute2 PAZ domain by NMR spectroscopy. Chemistry (Easton) 17, 1519–1528.

Manche, L., Green, S. R., Schmedt, C., and Mathews, M. B. (1992). Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell. Biol. 12, 5238–5248.

Maniatski, E., and Moureratos, Z. (2005). A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. Genes Dev. 19, 2979–2989.

Manoharan, M., Akine, A., Pandey, R. K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M. A., Nechev, L., Greene, E. M., Palan, P. S., Rozners, E., Rajeve, K. G., and Eglí, M. (2011). Unique gene-silencing and structural properties of 2′-fluoro-modified siRNAs. Angew. Chem. 50, 2284–2288.

Marques, J. T., Devosse, T., Wang, D., Zamanian-Daryoush, M., Serbinowski, P., Hartmann, R., Fujitani, T., Behlke, M. A., and Williams, B. R. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24, 539–545.

Martinez, J., Parkaniowski, A., Urlaub, H., Luhmann, R., and Tuschi, T. (2002). Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563–574.
Martinez, B. P., Lesnik, E. A., Gonzalez-Morrissey, D. V., Blanchard, K., Shaw, D. V., Lockridge, J. A., Shaw, D. V. (2004). Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell. 6, 1077–1087.

Peacock, H., Kannan, A., Beal, P. A., and Burrows, C. I. (2011). Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem. 76, 7295–7300.

Petersen, M., and Wengel, J. (2003). LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 21, 74–81.

Petri, S., Dueck, A., Lehmant, G., Putz, N., Rudel, S., Kremmer, E., and Meister, G. (2011). Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA 17, 737–749.

Petrova Kruglova, N. S., Meschanova, M. I., Venyaminova, A. G., Zenkova, M. A., Vlassov, V. Y., and Chernomolovskaya, E. I. (2010). 2′-O-methyl-modified anti-MDR1 fork-siRNA duplexes exhibit high RNA resistance and prolonged silencing activity. Oligonucleotides 20, 297–308.

Pirro, H., Prat, A., Zhou, Q., Hwang, S. H., Dagata, J. A., Zon, G., Hogrefe, R. I., Palchik, G., and Chang, E. H. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938–2943.

Potera, C. (2007). Antisense – down, but not out. Nat. Biotechnol. 25, 497–499.

Pradeepkumar, P. L., Amirikhanov, N. V., and Chattopadhyaya, J. (2003). Anti-sense oligonucleotides with overhang-containing cytidine enhance hetroduplex stability, and elicit satisfactory RNA N response as well as showing improved resistance to both endo and exonucleases. Org. Biomol. Chem. 1, 81–92.

Prakash, T. P., Allerson, C. R., Danne, P., Vickers, T. A., Souifi, N., Jarres, R., Baker, B. E., Swaye, E. E., Griffey, R. H., and Bhat, B. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247–4253.

Prakash, T. P., Kraynack, B., Baker, B. E., Swaye, E. E., and Bhat, B. (2006). RNA interference by 2′-5′-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett. 16, 3238–3240.

Putheveli, S., Whitby, L., Ren, J., Kel- nar, K., Krebs, J. F., and Beal, P. A. (2006). Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 34, 4900–4911.

Qu, L., Moreira, A., Kaplan, G., Levitz, R., Wang, J. Y., Xu, C., and Drlica, K. (1998). Degradation of hammerhead ribozymes by human ribonuclease. Mol. Gen. Genet. 258, 352–362.

Raemondck, K., Remaut, K., Lucas, B., Sanders, N. N., Demeester, J., and De Smidt, S. C. (2006). In situ analysis of single-stranded and duplex siRNA integrity in living cells. Biochemistry 45, 10614–10623.

Ranjith-Kumar, C. T., Miller, W., Xiong, J., Russell, W. K., Lamb, R., Santos, J., Duffy, K. E., Cleveland, L., Park, M., Bhardwaj, K., Wu, Z., Russell, D. H., Sarsky, R. T., Mbow, M. L., and Kao, C. C. (2007). Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J. Biol. Chem. 282, 7668–7678.

Reynolds, A., Anderson, E. M., Vermeulen, A., Fedorow, Y., Roskin, K., Leake, D., Karpilow, J., Marshall, W. S., and Khvorova, A. (2006). Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12, 988–993.

Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., and Khvorova, A. (2004). Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326–330.

Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworsky, E., Palmer, L., McClintock, K., and MacLachlan, I. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19, 991–999.

Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworsky, E., and MacLachlan, I. (2007). 2′-O-methyl-(M)modified RNAs act as TLK antagonists. Mol. Ther. 15, 1663–1669.

Rose, S. D., Kim, D. H., Amazegouzi, M., Heidel, J. D., CollingeWood, M. A., Davis, M. E., Rossi, J. I., and Behlke, M. A. (2005). Functional polarity is introduced by dicer processing of short substrate RNAs. Nucleic Acids Res. 33, 4110–4115.

Sanghvi, Y. S. (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr. Protoc. Nucleic Acid Chem. Chap. Unit 4, 1–22.

Schmidt, C. (2011). RNAi momentum fizzes asharma shifts priorities. Nat. Biotechnol. 29, 93–94.

Schwarz, D. S., Huvtagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P. D.
Sioud, M. (2005). Induction of inflammatory cytokines and interferon type I in primary macrophages. J. Virol. 77, 7174–7181.

Sorrentino, S. (1998). Human extra-cellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell. Mol. Life Sci. 54, 785–794.

Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, L., Levine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Rohl, I., Toudjarska, I., Wang, G., Wuscher, S., Bumcroft, D., Kotelskiy, V., Limmer, S., Manoharan, M., and Vornlocher, H. P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178.

Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., and Chattopadhyaya, J. (2007). Five- and six-membered conformationally locked 2′-arabocarbocyclic ribothymidines: synthesis, structure, and biochemical studies. J. Am. Chem. Soc. 129, 8362–8379.

Stein, C. A., and Krieg, A. M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligonucleotides. Antisense Res. Dev. 4, 67–69.

Strapp, W. R., Pickering, V., Muir, G. T., Rice, J., Orsborn, S., Polsky, B. A., Sachs, A., and Bartz, S. R. (2010). The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res. 38, 4788–4797.

Sun, X., Rogoff, H. A., and Li, C. J. (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol. 26, 1379–1382.

Swaye, E. E., Siwowskii, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., and Bennett, C. (2008). Five- and six-membered conformationally locked 2′-O-methyl oligoribonucleotides. Org. Biomol. Chem. 10, 746–754.

Takabatake, Y., Isaka, Y., Mizui, M., Kawahsi, H., Takahara, S., and Imai, E. (2007). Chemically modified siRNA prolonged RNA interference in renal disease. Biochem. Biophys. Res. Commun. 363, 432–437.

Takahashi, M., Minakawa, N., and Matsuda, A. (2009). Synthesis and characterization of 2′-modified-4′-thioRNA: a comprehensive comparison of nuclease stability. Nucleic Acids Res. 37, 1353–1362.

Thirkill, R. N., Torres, A. G., Krivenko, A., Gait, M. J., and Caruthers, M. H. (2012). Synthesis and biological activity of phosphorothioate- and thio phosphorothioate-modified 2′-O-methyl oligoribonucleotides. Org. Biomol. Chem. 10, 746–754.

Turner, J. J., Jones, S. W., Moschos, S. A., Lindsay, M. A., and Gait, M. J. (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biotechnol. 3, 43–50.

Utei, K., Naito, Y., Takahashi, F., Haraguchi, T., Okisi-Hamazaki, H., Juki, A., Ueda, R., and Saigo, K. (2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32, 936–948.

Utei, K., Naito, Y., Zennou, S., Nishi, K., Yamato, K., Takahashi, F., Juki, A., and Saigo, K. (2008). Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 36, 2136–2151.

Usberti, E. (1969). On the mechanism of ribonuclease action. Proc. Natl. Acad. Sci. U.S.A. 62, 661–667.

Vaish, N., Chen, F., Seth, S., Fossnaugh, K., Liu, Y., Adami, R., Brown, T., Chen, Y., Harvie, P., Johns, R., Severson, G., Granger, B., Charmley, P., Houston, M., Tempelin, M. V., and Polisky, B. (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleo-cobane analogs. Nucleic Acids Res. 39, 1823–1832.

van der Steeckom, J. C., Janssen, A. A., Ginjaz, L. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., Den Dunnen, J. T., Koop, K., Van Der Koos, A. J., Goemans, N. M., De Kimpe, S. J., Ekhart, P. F., van Necker, E. H., Platenburg, G. J., Ver- schuuren, J. I., and Van Ommen, G. J. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677–2686.

Vert, J. P., Foveau, L., Lajiaune, C., and Vandenbroucke, Y. (2006). An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7, 520. doi:10.1186/1471-2105-7-520

Vickers, T. A., Lima, W. F., Nichols, J. G., and Crooke, S. T. (2007). Reduced levels of AgO2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res. 35, 6598–6610.

Volk, A., Kugelov, N. S., Meschini- nova, M. I., Venyaminova, A. G., Zenkova, M. A., Vlassov, V. V., and Chernolovskaya, E. L. (2009). Selective protection of nuclelease-sensitive sites in siRNA prolongs
silencing effect. *Oligonucleotides* 19, 191–202.

Wang, L., Huang, C., and Yang, J. Y. (2010). Predicting siRNA potency with random forests and support vector machines. *BMC Genomics* 11(Suppl. 3), S2. doi:10.1186/1471-2164-11-S3-S2

Wang, X., Varma, R. K., Beauchamp, L., Magdaleno, S., and Sendera, T. J. (2009a). Selection of hyperfunctional siRNAs with improved potency and specificity. *Nucleic Acids Res.* 37, e152.

Wang, Y., Juranek, S., Li, H., Sheng, G., Wardle, G. S., Tuschl, T., and Patel, D. J. (2009b). Nucleation, propaga-

tion and cleavage of target RNAs in Ago silencing complexes. *Nature* 461, 754–761.

Wang, Y., Sheng, G., Juranek, S., Tuschl, T., and Patel, D. J. (2008). Struc-
ture of the guide-strand-containing argonaute silencing complex. *Nature* 456, 209–213.

Watts, J. K., Choudhary, N., Sadalapure, K., Robert, E., Wahba, A. S., Pel-
letier, J., Pinto, B. M., and Damha, M. J. (2007). 2′-Fluoro-4′-thioracabino-
modified oligonucleotides: confor-
mational switches linked to siRNA activity. *Nucleosides Nucleotides Nucleic Acids* Res. 35, 1441–1451.

Weber, C., Muller, C., Podszuszeit, A., Montino, C., Vollner, I., and Fos-
bach, A. (2012). Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). *Immunology* 136, 64–77.

Wei, J. X., Yang, L., Sun, J. F., Jia, L. T., Zhang, Y., Zhang, H. Z., Li, X., Meng, Y. L., Yao, L. B., and Yang, A. G. (2009). Both strands of siRNA have potential to guide posttranscrip-
tional gene silencing in mammalian cells. *PLoS ONE* 4, e5382. doi:10.1371/journal.pone.0005382

Wengel, J., Petersen, M., Nielsen, K. E., Jensen, G. A., Hakansson, A. E., Kumar, R., Sorensen, M. D., Rajwarshi, V. K., Bryld, T., and Jacobson, J. P. (2001). LNA (locked nucleic acid) and the diastereois-
meric alpha-t-LNA: conformational tuning and high-affinity recogni-
tion of DNA/RNA targets. *Nucleo-
sides Nucleotides Nucleic Acids* 20, 389–396.

Wilson, C., and Keefe, A. D. (2006). Building oligonucleotide therapeu-
tics using non-natural chemistries. *Curr. Opin. Chem. Biol.* 10, 607–614.

Wu, L., Fan, J., and Belasco, J. G. (2006). MicroRNAs direct rapid deadenyla-
tion of mRNA. *Proc. Natl. Acad. Sci. U.S.A.* 103, 4034–4039.

Yamada, C. M., Delling, D. I., and Caruthers, M. H. (2007). Syn-
thesis and biological activity of phosphonocarboxylate DNA. *Nucleo-
sides Nucleotides Nucleic Acids* 26, 539–546.

Yang, X., Sierant, M., Janicka, M., Peczko, L., Martinez, C., Hassell, T., Li, N., Li, X., Wang, T., and Nawrot, B. (2012). Gene silencing activity of siRNA molecules containing phos-
phorodithioate substitutions. *ACS Chem. Biol.* 7, 1214–1220.

Yoo, J. W., Kim, S., and Lee, D. K. (2008). Competition potency of siRNA is specified by the 5′-half sequence of the guide strand. *Biochem. Biophys. Res. Commun.* 367, 78–83.

Zamanian-Daryoush, M., Marques, J. T., Gantier, M. P., Behlke, M. A., John, M., Rayman, P., Finke, J., and Williams, B. R. (2008). Deter-
minants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. *J. Interferon Cytokine Res.* 28, 221–233.

Zamecnik, P. C., and Stephenson, M. L. (1978). Inhibition of Rous sarcoma virus replication and cell transfor-
mation by a specific oligodeoxynu-
clotide. *Proc. Natl. Acad. Sci. U.S.A.* 75, 280–284.

Zhang, Z., Weinschenk, T., Guo, K., and Schieseners, H. J. (2006). siRNA binding proteins of microbial cells: PKR is an unanticipated ligand. *J. Cell Biochem.* 97, 1217–1229.

Zimmer, S., Steinmetz, M., Asdonk, T., Motz, I., Coch, C., Hartmann, E., Barchet, W., Wassmann, S., Hart-
mann, G., and Nickenig, G. (2011). Activation of endothelial toll-like receptor 3 impairs endothelial func-
tion. *Circ. Res.* 108, 1358–1366.

Zimmermann, T. S., Lee, A. C., Akinc, A., Bramlage, B., Bumcrn, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClinton, K., Nechev, L. V., Palmer, L. R., Racie, T., Rohl, I., Sehift, S., Shmamgkam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. I., Yaworski, E., Zedalis, W., Koteliaysky, V., Manoharan, M., Vornlocher, H. P., and MacLachlan, I. (2006). siRNA-mediated gene silenc-
ing in non-human primates. *Nature* 441, 111–114.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any com-
mercial or financial relationships that could be construed as a potential con-
flict of interest.

Received: 10 May 2012; accepted: 31 July 2012; published online: 20 August 2012.

Citation: Bramsen JB and Kjems J (2012) Development of therapeutic-grade small interfering RNAs by chemical engineering. Front. Gene. 3:154. doi: 10.3389/fgene.2012.00154

This article was submitted to Frontiers in Non-Coding RNA, a specialty of Frontiers in Genetics.

Copyright © 2012 Bramsen and Kjems. This is an open-access article distributed under the terms of the Creative Com-
mons Attribution License, which per-
mits use, distribution and reproduction in other forums, provided the original authors and source are credited and sub-
ject to any copyright notices concerning any third-party graphics etc.